Abstract
1113P Post hoc survival outcomes based on initial and subsequent treatment in patients (pts) with mismatch repair proficient/microsatellite stable (MMRp/MSS) primary advanced or recurrent endometrial cancer (pA/R EC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
Annals of oncology, Vol.36(Suppl 2), pp.S740-S740
09/2025
DOI: 10.1016/j.annonc.2025.08.1750
Abstract
Background
Dostarlimab + carboplatin-paclitaxel (D+CP) is the only immunotherapy (IO) + chemotherapy (CT) combination to report significant overall survival (OS) benefits in pts with pA/R EC as shown in Part 1 of the phase 3 RUBY trial (NCT03981796). With global approvals for this frontline regimen, treatment sequencing and outcomes of subsequent treatments post-IO are of interest. We present post hoc analyses of outcomes based on the most common follow-up anticancer therapies (FUACTs) in RUBY Part 1.
Methods
Pts were randomized 1:1 to receive D+CP or placebo (P)+CP Q3W (6 cycles) followed by D or P monotherapy Q6W for ≤3 years. At the 22Sep2023 data cut, efficacy analyses were conducted for a subgroup of pts in the MMRp/MSS population who progressed and received either of the 2 most common FUACTs: pembrolizumab + lenvatinib (Pem/L; most common IO) or CT (most common FUACT).
Results
376 pts were enrolled with MMRp/MSS pA/R EC. At data cut, fewer pts (53.6%;103/192) in the D+CP arm had progressed vs P+CP (72.3%; 133/184). For pts receiving FUACT following progression, Pem/L and CT were received by 19/83 (22.9%) and 49/83 pts (59.0%), respectively, in the D+CP arm and by 40/116 (34.5%) and 53/116 pts (45.7%), respectively, in the P+CP arm. Median OS and 24-mo probability of OS were similar for FUACT with Pem/L or CT within each arm; OS outcomes favored D+CP vs P+CP regardless of FUACT, including Pem/L (Table).
Conclusions
In the difficult-to-treat MMRp/MSS population, pts receiving D+CP as initial systemic therapy had the longest OS outcomes in RUBY, with median OS improvement of 7 mo vs P+CP. Survival outcomes in MMRp/MSS pts receiving post-progression Pem/L or CT were similar in the D+CP arm and longer vs the P+CP arm. These findings suggest dostarlimab+CP used first achieves the longest survival and support its use as a standard of care in all pts with pA/R EC.
Details
- Title: Subtitle
- 1113P Post hoc survival outcomes based on initial and subsequent treatment in patients (pts) with mismatch repair proficient/microsatellite stable (MMRp/MSS) primary advanced or recurrent endometrial cancer (pA/R EC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
- Creators
- M.A. Powell - Washington University in St. Louis School of MedicineH. Roed - Copenhagen University HospitalL. Gilbert - McGill University Health CentreO. Zub - Department of Oncology, Chernihiv Medical Center of Modern Oncology, Chernihiv Regional Council, Chernihiv, UkraineC. McCourt - Washington University in St. Louis School of MedicineE. Fleming - Dartmouth–Hitchcock Medical CenterR. Angioli - Università Campus Bio-MedicoN. Cloven - Department of Gynecologic Oncology, Texas Oncology, Fort Worth, United States of AmericaD. Denschlag - Head of the Department OB/GYN, Director of Breast and Gynecologic Oncology Cancer Center, Hochtaunus-kliniken, Bad Homburg, GermanyK. Pennington - University of Washington School of MedicineA. Auranen - Tampere University HospitalB. Sawyer - Department of Gynecologic Oncology, Texas Oncology, Dallas, United States of AmericaC. Billingsley - University of Cincinnati Medical CenterD. Bender - University of IowaF. Backes - The Ohio State UniversityG. Canturia - Northside HospitalG. Antony - GlaxoSmithKlineL. Austin - GlaxoSmithKlineB.J. Monk - Gynecologic Oncology GroupM.R. Mirza - Copenhagen University Hospital
- Resource Type
- Abstract
- Publication Details
- Annals of oncology, Vol.36(Suppl 2), pp.S740-S740
- DOI
- 10.1016/j.annonc.2025.08.1750
- ISSN
- 0923-7534
- eISSN
- 1569-8041
- Publisher
- Elsevier Ltd
- Grant note
- GSK
Funding: GSK.
- Language
- English
- Date published
- 09/2025
- Academic Unit
- Obstetrics and Gynecology
- Record Identifier
- 9985035032902771
Metrics
6 Record Views